Search
Aripiprazole
go.drugbank.com/drugs/DB01238ApprovedInvestigationalAripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. … [L45859] It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, P-glycoprotein inhibitorsProducts: Nb-aripiprazole, ABILIFY 7.5 MG/ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADETLincomycin
go.drugbank.com/drugs/DB01627ApprovedInvestigationalVet approved[A190657, A190621] Lincomycin was approved by the FDA on December 29, 1964.[L33214] … [A190621] Clinical use of lincomycin has largely been superseded by its semisynthetic derivative [clindamycin] due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains
Categories: Heterocyclic Compounds, 1-RingProducts: LINCOCIN 600 MG IM/IV AMPUL, 1 ADET, LINCOCIN 2 ML 600 MG 1 AMPULPlazomicin
go.drugbank.com/drugs/DB12615ApprovedIt mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis [FDA Label]. … Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from [DB12604].
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsEflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawn[A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric … [A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA for the treatment of African trypanosomiasis and hirsutism, respectively, but has since been discontinued
Synonyms: 2-(difluoromethyl)ornithine, α-difluoromethylornithineViltolarsen
go.drugbank.com/drugs/DB15005ApprovedInvestigationalDuchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function … Viltolarsen was developed by Nippon Shinyaku Co LTD and is being marketed under the name VILTEPSO™.[L15526]
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigational[L53743] ITP is an autoimmune disorder characterized by low platelet count. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile, (3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-?-[2-methyl-2-[4-(3-oxetanyl)-1-piperazinyl]propylidene]-?-oxo-1-piperidinepropanenitrileIdebenone
go.drugbank.com/drugs/DB09081ApprovedInvestigationalDue to its biochemical mode of action, it's thought that idebenone may re-activate viable-but-inactive retinal ganglion cells (RGCs) in LHON patients [L885]. … It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada.
Mixtures: EVERON 90/5 MG FILM KAPLI TABLET ,50 TABLET, EVERON 90/5 MG FILM KAPLI TABLET ,100 TABLETCategories: Compounds used in a research, industrial, or household settingOmalizumab
go.drugbank.com/drugs/DB00043ApprovedInvestigationalBy binding to IgE and neutralizing it, omalizumab reduces free IgE levels and prevents IgE from binding to its receptors on immune cells. … [A39518] Omalizumab was first approved in the US in 2003 [A263507] and in Europe in 2005.
Categories: Agents to Treat Airway DiseaseProducts: XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/1.0ML, XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5MLMidazolam
go.drugbank.com/drugs/DB00683ApprovedIllicitInvestigational[F2977] This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. … and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: N/a, DEMIZOLAM 5 MG/5 ML IV/IM ENJEKTABL SOLUSYON ICEREN AMPUL, 5 ADETLormetazepam
go.drugbank.com/drugs/DB13872ApprovedLormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia [L927]. … It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.
Categories: Heterocyclic Compounds, 2-RingSynonyms: N-Methyllorazepam, 7-Chloro-1,3-dihydro-5-(o-chlorophenyl)-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one